Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Founding editor of ecancermedicalscience, Prof Gordon McVie, discusses the top articles of the month, including:
Circulating tumour cells in breast cancer
Measuring patient-reported outcomes in advanced gastric cancer
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
ESMO 2024: Highlights and analysis
ESMO 2023: Highlights and analysis
OncoAlert round up July 28th to August 3rd, 2023
Updates on HR-positive HER2-negative breast cancer
ASCO 2023: Highlights and analysis